IBDEI1LZ ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.4,179,0)
;;=MEDICATION ADMIN^7^19
;;^UTILITY(U,$J,358.4,180,0)
;;=IMMUNIZATION ADMINISTRATION^5^19
;;^UTILITY(U,$J,358.4,181,0)
;;=IMMUNIZATIONS^6^19
;;^UTILITY(U,$J,358.4,182,0)
;;=CONTINUOUS GLUCOSE MONITORING^3^19
;;^UTILITY(U,$J,358.4,183,0)
;;=ANTICOAGULATION^2^20
;;^UTILITY(U,$J,358.4,184,0)
;;=PAIN^6^20
;;^UTILITY(U,$J,358.4,185,0)
;;=MENTAL HEALTH^5^20
;;^UTILITY(U,$J,358.4,186,0)
;;=ENDOCRINE^4^20
;;^UTILITY(U,$J,358.4,187,0)
;;=CARDIOVASCULAR^3^20
;;^UTILITY(U,$J,358.4,188,0)
;;=RESPIRATORY^7^20
;;^UTILITY(U,$J,358.4,189,0)
;;=OTHER^8^20
;;^UTILITY(U,$J,358.4,190,0)
;;=COMMON DIAGNOSIS^1^20
;;^UTILITY(U,$J,358.4,191,0)
;;=NEW PATIENT^3^21
;;^UTILITY(U,$J,358.4,192,0)
;;=ESTABLISHED PATIENT^1^21
;;^UTILITY(U,$J,358.4,193,0)
;;=CONSULTATIONS^2^21
;;^UTILITY(U,$J,358.4,194,0)
;;=PREVENTIVE MEDICINE-EST PT^4^21
;;^UTILITY(U,$J,358.4,195,0)
;;=PREVENTIVE MEDICINE-NEW PT^5^21
;;^UTILITY(U,$J,358.4,196,0)
;;=RISK FACTOR REDUCTION-GRP^6^21
;;^UTILITY(U,$J,358.4,197,0)
;;=RISK FACTOR REDUCTION-IND^7^21
;;^UTILITY(U,$J,358.4,198,0)
;;=OTHER^3^22
;;^UTILITY(U,$J,358.4,199,0)
;;=EDUCATION/TRAINING^1^22
;;^UTILITY(U,$J,358.4,200,0)
;;=MEDICAL NUTRITION THERAPY^2^22
;;^UTILITY(U,$J,358.4,201,0)
;;=WOUND TREATMENT^5^22
;;^UTILITY(U,$J,358.4,202,0)
;;=PROLONGED SERVICES^4^22
;;^UTILITY(U,$J,358.4,203,0)
;;=DIABETES^1^23
;;^UTILITY(U,$J,358.4,204,0)
;;=SUICIDE IDEATIONS/ATTEMPTS^2^23
;;^UTILITY(U,$J,358.4,205,0)
;;=NEW PATIENT^3^24
;;^UTILITY(U,$J,358.4,206,0)
;;=ESTABLISHED PATIENT^2^24
;;^UTILITY(U,$J,358.4,207,0)
;;=CONSULTATIONS^4^24
;;^UTILITY(U,$J,358.4,208,0)
;;=PROVIDER WEEKLY VISIT^1^24
;;^UTILITY(U,$J,358.4,209,0)
;;=ACCESS^5^25
;;^UTILITY(U,$J,358.4,210,0)
;;=DIALYSIS PROCEDURES^6^25
;;^UTILITY(U,$J,358.4,211,0)
;;=ESRD HOME SERVICES^7^25
;;^UTILITY(U,$J,358.4,212,0)
;;=HEMODIALYSIS OVERSIGHT^1^25
;;^UTILITY(U,$J,358.4,213,0)
;;=LAB^9^25
;;^UTILITY(U,$J,358.4,214,0)
;;=MEDICATIONS^10^25
;;^UTILITY(U,$J,358.4,215,0)
;;=MONITORING^11^25
;;^UTILITY(U,$J,358.4,216,0)
;;=OTHER^12^25
;;^UTILITY(U,$J,358.4,217,0)
;;=PATIENT EDUCATION/TEACHING^13^25
;;^UTILITY(U,$J,358.4,218,0)
;;=PATIENT MANAGEMENT^14^25
;;^UTILITY(U,$J,358.4,219,0)
;;=SUPPLIES^16^25
;;^UTILITY(U,$J,358.4,220,0)
;;=VACCINATIONS^17^25
;;^UTILITY(U,$J,358.4,221,0)
;;=DAILY DIALYSIS TXMT^2^25
;;^UTILITY(U,$J,358.4,222,0)
;;=INPATIENT DIALYSIS^8^25
;;^UTILITY(U,$J,358.4,223,0)
;;=PERITONEAL DIALYSIS^3^25
;;^UTILITY(U,$J,358.4,224,0)
;;=TEAM CONFERENCE^4^25
;;^UTILITY(U,$J,358.4,225,0)
;;=PROLONGED SERVICES^15^25
;;^UTILITY(U,$J,358.4,226,0)
;;=HEMODIALYSIS-ESRD^14^26
;;^UTILITY(U,$J,358.4,227,0)
;;=PERITONEAL DIALYSIS ENCOUNTER^23^26
;;^UTILITY(U,$J,358.4,228,0)
;;=CARDIOLOGY/CARDIORENAL SYNDROME^2^26
;;^UTILITY(U,$J,358.4,229,0)
;;=COMPLICATIONS/OTHER^4^26
;;^UTILITY(U,$J,358.4,230,0)
;;=CYSTIC KIDNEY DISEASE^5^26
;;^UTILITY(U,$J,358.4,231,0)
;;=DIABETES/DIABETIC RENAL DISEASE^6^26
;;^UTILITY(U,$J,358.4,232,0)
;;=FLUID/ELECTROLYTE DISORDER^8^26
;;^UTILITY(U,$J,358.4,233,0)
;;=GENERAL SYMPTOMS^9^26
;;^UTILITY(U,$J,358.4,234,0)
;;=GENITAL/URINARY^10^26
;;^UTILITY(U,$J,358.4,235,0)
;;=HEMATOLOGY^12^26
;;^UTILITY(U,$J,358.4,236,0)
;;=HYPERTENSION^15^26
;;^UTILITY(U,$J,358.4,237,0)
;;=INFECTIOUS DISEASE^16^26
;;^UTILITY(U,$J,358.4,238,0)
;;=NEPHRITIS GLUMERULONEPHRITIS^18^26
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1LZ 3807 printed Sep 23, 2025@19:47:19 Page 2
IBDEI1LZ ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.4)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.4,179,0)
+2 ;;=MEDICATION ADMIN^7^19
+3 ;;^UTILITY(U,$J,358.4,180,0)
+4 ;;=IMMUNIZATION ADMINISTRATION^5^19
+5 ;;^UTILITY(U,$J,358.4,181,0)
+6 ;;=IMMUNIZATIONS^6^19
+7 ;;^UTILITY(U,$J,358.4,182,0)
+8 ;;=CONTINUOUS GLUCOSE MONITORING^3^19
+9 ;;^UTILITY(U,$J,358.4,183,0)
+10 ;;=ANTICOAGULATION^2^20
+11 ;;^UTILITY(U,$J,358.4,184,0)
+12 ;;=PAIN^6^20
+13 ;;^UTILITY(U,$J,358.4,185,0)
+14 ;;=MENTAL HEALTH^5^20
+15 ;;^UTILITY(U,$J,358.4,186,0)
+16 ;;=ENDOCRINE^4^20
+17 ;;^UTILITY(U,$J,358.4,187,0)
+18 ;;=CARDIOVASCULAR^3^20
+19 ;;^UTILITY(U,$J,358.4,188,0)
+20 ;;=RESPIRATORY^7^20
+21 ;;^UTILITY(U,$J,358.4,189,0)
+22 ;;=OTHER^8^20
+23 ;;^UTILITY(U,$J,358.4,190,0)
+24 ;;=COMMON DIAGNOSIS^1^20
+25 ;;^UTILITY(U,$J,358.4,191,0)
+26 ;;=NEW PATIENT^3^21
+27 ;;^UTILITY(U,$J,358.4,192,0)
+28 ;;=ESTABLISHED PATIENT^1^21
+29 ;;^UTILITY(U,$J,358.4,193,0)
+30 ;;=CONSULTATIONS^2^21
+31 ;;^UTILITY(U,$J,358.4,194,0)
+32 ;;=PREVENTIVE MEDICINE-EST PT^4^21
+33 ;;^UTILITY(U,$J,358.4,195,0)
+34 ;;=PREVENTIVE MEDICINE-NEW PT^5^21
+35 ;;^UTILITY(U,$J,358.4,196,0)
+36 ;;=RISK FACTOR REDUCTION-GRP^6^21
+37 ;;^UTILITY(U,$J,358.4,197,0)
+38 ;;=RISK FACTOR REDUCTION-IND^7^21
+39 ;;^UTILITY(U,$J,358.4,198,0)
+40 ;;=OTHER^3^22
+41 ;;^UTILITY(U,$J,358.4,199,0)
+42 ;;=EDUCATION/TRAINING^1^22
+43 ;;^UTILITY(U,$J,358.4,200,0)
+44 ;;=MEDICAL NUTRITION THERAPY^2^22
+45 ;;^UTILITY(U,$J,358.4,201,0)
+46 ;;=WOUND TREATMENT^5^22
+47 ;;^UTILITY(U,$J,358.4,202,0)
+48 ;;=PROLONGED SERVICES^4^22
+49 ;;^UTILITY(U,$J,358.4,203,0)
+50 ;;=DIABETES^1^23
+51 ;;^UTILITY(U,$J,358.4,204,0)
+52 ;;=SUICIDE IDEATIONS/ATTEMPTS^2^23
+53 ;;^UTILITY(U,$J,358.4,205,0)
+54 ;;=NEW PATIENT^3^24
+55 ;;^UTILITY(U,$J,358.4,206,0)
+56 ;;=ESTABLISHED PATIENT^2^24
+57 ;;^UTILITY(U,$J,358.4,207,0)
+58 ;;=CONSULTATIONS^4^24
+59 ;;^UTILITY(U,$J,358.4,208,0)
+60 ;;=PROVIDER WEEKLY VISIT^1^24
+61 ;;^UTILITY(U,$J,358.4,209,0)
+62 ;;=ACCESS^5^25
+63 ;;^UTILITY(U,$J,358.4,210,0)
+64 ;;=DIALYSIS PROCEDURES^6^25
+65 ;;^UTILITY(U,$J,358.4,211,0)
+66 ;;=ESRD HOME SERVICES^7^25
+67 ;;^UTILITY(U,$J,358.4,212,0)
+68 ;;=HEMODIALYSIS OVERSIGHT^1^25
+69 ;;^UTILITY(U,$J,358.4,213,0)
+70 ;;=LAB^9^25
+71 ;;^UTILITY(U,$J,358.4,214,0)
+72 ;;=MEDICATIONS^10^25
+73 ;;^UTILITY(U,$J,358.4,215,0)
+74 ;;=MONITORING^11^25
+75 ;;^UTILITY(U,$J,358.4,216,0)
+76 ;;=OTHER^12^25
+77 ;;^UTILITY(U,$J,358.4,217,0)
+78 ;;=PATIENT EDUCATION/TEACHING^13^25
+79 ;;^UTILITY(U,$J,358.4,218,0)
+80 ;;=PATIENT MANAGEMENT^14^25
+81 ;;^UTILITY(U,$J,358.4,219,0)
+82 ;;=SUPPLIES^16^25
+83 ;;^UTILITY(U,$J,358.4,220,0)
+84 ;;=VACCINATIONS^17^25
+85 ;;^UTILITY(U,$J,358.4,221,0)
+86 ;;=DAILY DIALYSIS TXMT^2^25
+87 ;;^UTILITY(U,$J,358.4,222,0)
+88 ;;=INPATIENT DIALYSIS^8^25
+89 ;;^UTILITY(U,$J,358.4,223,0)
+90 ;;=PERITONEAL DIALYSIS^3^25
+91 ;;^UTILITY(U,$J,358.4,224,0)
+92 ;;=TEAM CONFERENCE^4^25
+93 ;;^UTILITY(U,$J,358.4,225,0)
+94 ;;=PROLONGED SERVICES^15^25
+95 ;;^UTILITY(U,$J,358.4,226,0)
+96 ;;=HEMODIALYSIS-ESRD^14^26
+97 ;;^UTILITY(U,$J,358.4,227,0)
+98 ;;=PERITONEAL DIALYSIS ENCOUNTER^23^26
+99 ;;^UTILITY(U,$J,358.4,228,0)
+100 ;;=CARDIOLOGY/CARDIORENAL SYNDROME^2^26
+101 ;;^UTILITY(U,$J,358.4,229,0)
+102 ;;=COMPLICATIONS/OTHER^4^26
+103 ;;^UTILITY(U,$J,358.4,230,0)
+104 ;;=CYSTIC KIDNEY DISEASE^5^26
+105 ;;^UTILITY(U,$J,358.4,231,0)
+106 ;;=DIABETES/DIABETIC RENAL DISEASE^6^26
+107 ;;^UTILITY(U,$J,358.4,232,0)
+108 ;;=FLUID/ELECTROLYTE DISORDER^8^26
+109 ;;^UTILITY(U,$J,358.4,233,0)
+110 ;;=GENERAL SYMPTOMS^9^26
+111 ;;^UTILITY(U,$J,358.4,234,0)
+112 ;;=GENITAL/URINARY^10^26
+113 ;;^UTILITY(U,$J,358.4,235,0)
+114 ;;=HEMATOLOGY^12^26
+115 ;;^UTILITY(U,$J,358.4,236,0)
+116 ;;=HYPERTENSION^15^26
+117 ;;^UTILITY(U,$J,358.4,237,0)
+118 ;;=INFECTIOUS DISEASE^16^26
+119 ;;^UTILITY(U,$J,358.4,238,0)
+120 ;;=NEPHRITIS GLUMERULONEPHRITIS^18^26
